I04-1-Macromolecular Crystallography (fixed wavelength)
|
Nathan
Rose
,
Esther C. Y.
Woon
,
Anthony
Tumber
,
Louise J.
Walport
,
Rasheduzzaman
Chowdhury
,
Xuan Shirley
Li
,
Oliver N. F.
King
,
Clarisse
Lejeune
,
Stanley
Ng
,
Tobias
Krojer
,
Mun Chiang
Chan
,
Anna M.
Rydzik
,
Richard J.
Hopkinson
,
Ka Hing
Che
,
Michelle
Daniel
,
Claire
Strain-Damerell
,
Carina
Gileadi
,
Grazyna
Kochan
,
Ivanhoe K. H.
Leung
,
James
Dunford
,
Kar Kheng
Yeo
,
Peter J.
Ratcliffe
,
Nicola
Burgess-Brown
,
Frank
Von Delft
,
Susanne
Muller
,
Brian
Marsden
,
Paul. E.
Brennan
,
Michael A.
Mcdonough
,
Udo
Oppermann
,
Robert J.
Klose
,
Christopher J.
Schofield
,
Akane
Kawamura
Diamond Proposal Number(s):
[7495]
Abstract: The JmjC oxygenases catalyze the N-demethylation of Nε-methyl lysine residues in histones and are current therapeutic targets. A
SET of human 2-oxoglutarate analogues were screened using a unified assay platform for JmjC demethylases and related oxygenases. Results led to the finding that daminozide (N-(dimethylamino)succinamic acid, 160 Da), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily. Kinetic and crystallographic studies reveal that daminozide chelates the active site metal via its hydrazide carbonyl and dimethylamino groups.
|
Jul 2012
|
|
I02-Macromolecular Crystallography
I04-Macromolecular Crystallography
|
Thomas
Mccorvie
,
Jolanta
Kopec
,
S J
Hyung
,
Fiona
Fitzpatrick
,
X
Feng
,
D.
Termine
,
C.
Strain-Damerell
,
Melanie
Vollmar
,
J.
Fleming
,
J. M.
Janz
,
C.
Bulawa
,
Wyatt
Yue
Diamond Proposal Number(s):
[8421, 10619]
Open Access
Abstract: Cystathionine β-synthase (CBS) is a key enzyme in sulfur metabolism, and its inherited deficiency causes homocystinuria. Mammalian CBS is modulated by the binding of S-adenosyl-l-methionine (AdoMet) to its regulatory domain, which activates its catalytic domain. To investigate the underlying mechanism, we performed x-ray crystallography, mutagenesis, and mass spectrometry (MS) on human CBS. The 1.7 Å structure of a AdoMet-bound CBS regulatory domain shows one AdoMet molecule per monomer, at the interface between two constituent modules (CBS-1, CBS-2). AdoMet binding is accompanied by a reorientation between the two modules, relative to the AdoMet-free basal state, to form interactions with AdoMet via residues verified by mutagenesis to be important for AdoMet binding (Phe443, Asp444, Gln445, and Asp538) and for AdoMet-driven inter-domain communication (Phe443, Asp538). The observed structural change is further supported by ion mobility MS, showing that as-purified CBS exists in two conformational populations, which converged to one in the presence of AdoMet. We therefore propose that AdoMet-induced conformational change alters the interface and arrangement between the catalytic and regulatory domains within the CBS oligomer, thereby increasing the accessibility of the enzyme active site for catalysis.
|
Dec 2014
|
|
B21-High Throughput SAXS
I02-Macromolecular Crystallography
I03-Macromolecular Crystallography
I04-1-Macromolecular Crystallography (fixed wavelength)
I04-Macromolecular Crystallography
|
Catrine
Johansson
,
Velupillai
Srikannathasan
,
Anthony
Tumber
,
Aleksandra
Szykowska
,
Edward S.
Hookway
,
Radoslaw
Nowak
,
Claire
Strain-Damerell
,
Carina
Gileadi
,
Martin
Philpott
,
Nicola
Burgess-Brown
,
Na
Wu
,
Jolanta
Kopec
,
Andrea
Nuzzi
,
Holger
Steuber
,
Ursula
Egner
,
Volker
Badock
,
Shonagh
Munro
,
Nicholas B
Lathangue
,
Sue
Westaway
,
Jack
Brown
,
Nick
Athanasou
,
Rab
Prinjha
,
Paul E
Brennan
,
Udo
Oppermann
Diamond Proposal Number(s):
[10619]
Abstract: Members of the KDM5 (also known as JARID1) family are 2-oxoglutarate- and Fe2+-dependent oxygenases that act as histone H3K4 demethylases, thereby regulating cell proliferation and stem cell self-renewal and differentiation. Here we report crystal structures of the catalytic core of the human KDM5B enzyme in complex with three inhibitor chemotypes. These scaffolds exploit several aspects of the KDM5 active site, and their selectivity profiles reflect their hybrid features with respect to the KDM4 and KDM6 families. Whereas GSK-J1, a previously identified KDM6 inhibitor, showed about sevenfold less inhibitory activity toward KDM5B than toward KDM6 proteins, KDM5-C49 displayed 25–100-fold selectivity between KDM5B and KDM6B. The cell-permeable derivative KDM5-C70 had an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels. The selective inhibitor GSK467 exploited unique binding modes, but it lacked cellular potency in the myeloma system. Taken together, these structural leads deliver multiple starting points for further rational and selective inhibitor design.
|
May 2016
|
|
I02-Macromolecular Crystallography
|
Anthony
Tumber
,
Andrea
Nuzzi
,
Edward S.
Hookway
,
Stephanie B.
Hatch
,
Srikannathasan
Velupillai
,
Catrine
Johansson
,
Akane
Kawamura
,
Pavel
Savitsky
,
Clarence
Yapp
,
Aleksandra
Szykowska
,
Na
Wu
,
Chas
Bountra
,
Claire
Strain-Damerell
,
Nicola A.
Burgess-Brown
,
Gian Filippo
Ruda
,
Oleg
Fedorov
,
Shonagh
Munro
,
Katherine S.
England
,
Radoslaw P.
Nowak
,
Christopher J.
Schofield
,
Nicholas B.
La Thangue
,
Charlotte
Pawlyn
,
Faith
Davies
,
Gareth
Morgan
,
Nick
Athanasou
,
Susanne
Müller
,
Udo
Oppermann
,
Paul E.
Brennan
Open Access
Abstract: Methylation of lysine residues on histone tail is a dynamic epigenetic modification that plays a key role in chromatin structure and gene regulation. Members of the KDM5 (also known as JARID1) sub-family are 2-oxoglutarate (2-OG) and Fe2+-dependent oxygenases acting as histone 3 lysine 4 trimethyl (H3K4me3) demethylases, regulating proliferation, stem cell self-renewal, and differentiation. Here we present the characterization of KDOAM-25, an inhibitor of KDM5 enzymes. KDOAM-25 shows biochemical half maximal inhibitory concentration values of <100 nM for KDM5A-D in vitro, high selectivity toward other 2-OG oxygenases sub-families, and no off-target activity on a panel of 55 receptors and enzymes. In human cell assay systems, KDOAM-25 has a half maximal effective concentration of ∼50 μM and good selectivity toward other demethylases. KDM5B is overexpressed in multiple myeloma and negatively correlated with the overall survival. Multiple myeloma MM1S cells treated with KDOAM-25 show increased global H3K4 methylation at transcriptional start sites and impaired proliferation.
|
Mar 2017
|
|
I04-1-Macromolecular Crystallography (fixed wavelength)
|
Anthony R.
Bradley
,
Aude
Echalier
,
Michael
Fairhead
,
Claire
Strain-Damerell
,
Paul
Brennan
,
Alex n.
Bullock
,
Nicola a.
Burgess-Brown
,
Elizabeth P.
Carpenter
,
Opher
Gileadi
,
Brian d.
Marsden
,
Wen hwa
Lee
,
Wyatt
Yue
,
Chas
Bountra
,
Frank
Von Delft
Open Access
Abstract: The ongoing explosion in genomics data has long since outpaced the capacity of conventional biochemical methodology to verify the large number of hypotheses that emerge from the analysis of such data. In contrast, it is still a gold-standard for early phenotypic validation towards small-molecule drug discovery to use probe molecules (or tool compounds), notwithstanding the difficulty and cost of generating them. Rational structure-based approaches to ligand discovery have long promised the efficiencies needed to close this divergence; in practice, however, this promise remains largely unfulfilled, for a host of well-rehearsed reasons and despite the huge technical advances spearheaded by the structural genomics initiatives of the noughties. Therefore the current, fourth funding phase of the Structural Genomics Consortium (SGC), building on its extensive experience in structural biology of novel targets and design of protein inhibitors, seeks to redefine what it means to do structural biology for drug discovery. We developed the concept of a Target Enabling Package (TEP) that provides, through reagents, assays and data, the missing link between genetic disease linkage and the development of usefully potent compounds. There are multiple prongs to the ambition: rigorously assessing targets’ genetic disease linkages through crowdsourcing to a network of collaborating experts; establishing a systematic approach to generate the protocols and data that comprise each target’s TEP; developing new, X-ray-based fragment technologies for generating high quality chemical matter quickly and cheaply; and exploiting a stringently open access model to build multidisciplinary partnerships throughout academia and industry. By learning how to scale these approaches, the SGC aims to make structures finally serve genomics, as originally intended, and demonstrate how 3D structures systematically allow new modes of druggability to be discovered for whole classes of targets.
|
Nov 2017
|
|
I04-1-Macromolecular Crystallography (fixed wavelength)
I04-Macromolecular Crystallography
I24-Microfocus Macromolecular Crystallography
|
Yin Yao
Dong
,
Hua
Wang
,
Ashley C. W.
Pike
,
Stephen A.
Cochrane
,
Sadra
Hamedzadeh
,
Filip J.
Wyszyński
,
Simon R.
Bushell
,
Sylvain F.
Royer
,
David A.
Widdick
,
Andaleeb
Sajid
,
Helena I.
Boshoff
,
Yumi
Park
,
Ricardo
Lucas
,
Wei-Min
Liu
,
Seung Seo
Lee
,
Takuya
Machida
,
Leanne
Minall
,
Shahid
Mehmood
,
Katsiaryna
Belaya
,
Wei-Wei
Liu
,
Amy
Chu
,
Leela
Shrestha
,
Shubhashish M. M.
Mukhopadhyay
,
Claire
Strain-Damerell
,
Rod
Chalk
,
Nicola A.
Burgess-Brown
,
Mervyn J.
Bibb
,
Clifton E.
Barry
,
Carol V.
Robinson
,
David
Beeson
,
Benjamin G.
Davis
,
Elizabeth P.
Carpenter
Diamond Proposal Number(s):
[10619, 15433, 19301]
Open Access
Abstract: Protein N-glycosylation is a widespread post-translational modification. The first committed step in this process is catalysed by dolichyl-phosphate N-acetylglucosamine-phosphotransferase DPAGT1 (GPT/E.C. 2.7.8.15). Missense DPAGT1 variants cause congenital myasthenic syndrome and disorders of glycosylation. In addition, naturally-occurring bactericidal nucleoside analogues such as tunicamycin are toxic to eukaryotes due to DPAGT1 inhibition, preventing their clinical use. Our structures of DPAGT1 with the substrate UDP-GlcNAc and tunicamycin reveal substrate binding modes, suggest a mechanism of catalysis, provide an understanding of how mutations modulate activity (thus causing disease) and allow design of non-toxic ‘lipid-altered’ tunicamycins. The structure-tuned activity of these analogues against several bacterial targets allowed the design of potent antibiotics for Mycobacterium tuberculosis, enabling treatment in vitro, in cellulo and in vivo, providing a promising new class of antimicrobial drug.
|
Nov 2018
|
|
B21-High Throughput SAXS
|
Diamond Proposal Number(s):
[21035, 10619]
Open Access
Abstract: The core machinery for de novo biosynthesis of iron-sulfur clusters (ISC), located in the mitochondria matrix, is a five-protein complex containing the cysteine desulfurase NFS1 that is activated by frataxin (FXN), scaffold protein ISCU, accessory protein ISD11, and acyl-carrier protein ACP. Deficiency in FXN leads to the loss-of-function neurodegenerative disorder Friedreich’s ataxia (FRDA). Here the 3.2 Å resolution cryo-electron microscopy structure of the FXN-bound active human complex, containing two copies of the NFS1-ISD11-ACP-ISCU-FXN hetero-pentamer, delineates the interactions of FXN with other component proteins of the complex. FXN binds at the interface of two NFS1 and one ISCU subunits, modifying the local environment of a bound zinc ion that would otherwise inhibit NFS1 activity in complexes without FXN. Our structure reveals how FXN facilitates ISC production through stabilizing key loop conformations of NFS1 and ISCU at the protein–protein interfaces, and suggests how FRDA clinical mutations affect complex formation and FXN activation.
|
May 2019
|
|
|
|
Abstract: This chapter describes the step-by-step methods employed by the Structural Genomics Consortium (SGC) for screening and producing proteins in the baculovirus expression vector system (BEVS). This eukaryotic expression system was selected and a screening process established in 2007 as a measure to tackle the more challenging kinase, RNA–DNA processing, and integral membrane protein families on our target list. Here, we discuss our platform for identifying soluble proteins from 3 mL of insect cell culture and describe the procedures involved in producing protein from liter-scale cultures.
|
Oct 2020
|
|
|
|
Abstract: In Chapter 3, we described the Structural Genomics Consortium (SGC) process for generating multiple constructs of truncated versions of each protein using LIC. In this chapter we provide a step-by-step procedure of our E. coli system for test expressing intracellular (soluble) proteins in a 96-well format that enables us to identify which proteins or truncated versions are expressed in a soluble and stable form suitable for structural studies. In addition, we detail the process for scaling up cultures for large-scale protein purification. This level of production is required to obtain sufficient quantities (i.e., milligram amounts) of protein for further characterization and/or structural studies (e.g., crystallization or cryo-EM experiments). Our standard process is purification by immobilized metal affinity chromatography (IMAC) using nickel resin followed by size exclusion chromatography (SEC), with additional procedures arising from the complexity of the protein itself.
|
Oct 2020
|
|
|
|
Abstract: Structural genomics groups have identified the need to generate multiple truncated versions of each target to improve their success in producing a well-expressed, soluble, and stable protein and one that crystallizes and diffracts to a sufficient resolution for structural determination. At the Structural Genomics Consortium, we opted for the ligation-independent cloning (LIC) method which provides the throughput we desire to produce and screen many proteins in a parallel process. Here, we describe our LIC protocol for generating constructs in 96-well format and provide a choice of vectors suitable for expressing proteins in both E. coli and the baculovirus expression vector system (BEVS).
|
Oct 2020
|
|
